Cargando…

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Detalles Bibliográficos
Autores principales:	De Souza, Andre, Tavora, Fabio A., Mahalingam, Devalingam, Munster, Pamela N., Safran, Howard P., El-Deiry, Wafik S., Carneiro, Benedito A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604263/ https://www.ncbi.nlm.nih.gov/pubmed/33193448 http://dx.doi.org/10.3389/fimmu.2020.595289

Ejemplares similares

GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
por: Rudd, Christopher E.
Publicado: (2020)

Strategies to sensitize cancer cells to immunotherapy
por: George, Andrew, et al.
Publicado: (2021)

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma
por: Hsu, Andrew, et al.
Publicado: (2022)

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies
por: Odia, Yazmin, et al.
Publicado: (2022)

Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo
por: Jhaveri, Aakash V., et al.
Publicado: (2021)

AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer
por: Huntington, Kelsey E., et al.
Publicado: (2023)

GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer
por: Huntington, Kelsey E., et al.
Publicado: (2023)

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG
por: Zhang, Yiqun, et al.
Publicado: (2021)

Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer
por: Patel, Sukeshi, et al.
Publicado: (2016)

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD‐1/PDL‐1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer
por: Winer, Arthur, et al.
Publicado: (2019)

Investing in biomedical research is important
por: El-Deiry, Wafik S
Publicado: (2013)

Welcoming Paul Dent as Assistant Editor-in-Chief of Cancer Biology & Therapy
por: El-Deiry, Wafik S
Publicado: (2013)

Are we losing the war on cancer?
por: El-Deiry, Wafik S
Publicado: (2013)

Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible
por: El-Deiry, Wafik S.
Publicado: (2023)

A dual-targeting approach to inhibit Brucella abortus replication in human cells
por: Czyż, Daniel M., et al.
Publicado: (2016)

The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2015)

Review: Oncolytic virotherapy, updates and future directions
por: Fountzilas, Christos, et al.
Publicado: (2017)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

The tuberous sclerosis complex gets fatter
por: Gokare, Prashanth, et al.
Publicado: (2017)

Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology
por: El-Deiry, Wafik S., et al.
Publicado: (2021)

Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase
por: Zhao, Shuai, et al.
Publicado: (2021)

Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation
por: Carlsen, Lindsey, et al.
Publicado: (2022)

A Yeast GSK-3 Kinase Mck1 Promotes Cdc6 Degradation to Inhibit DNA Re-Replication
por: Ikui, Amy E., et al.
Publicado: (2012)

Regulation of the human TRAIL gene
por: Allen, Joshua E., et al.
Publicado: (2012)

Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin
por: Allen, Joshua E., et al.
Publicado: (2013)

Targeting Oncoproteins for Molecular Cancer Therapy
por: Allen, Joshua E., et al.
Publicado: (2016)

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

Inhibition of HIV-1 Replication and Dimerization Interference by Dual Inhibitory RNAs
por: Sánchez-Luque, Francisco J., et al.
Publicado: (2010)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
por: Costa, Rubens Barros, et al.
Publicado: (2018)

GSK3β Inhibition Ameliorates Atherosclerotic Calcification
por: Cai, Xinjiang, et al.
Publicado: (2023)

Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
por: Kline, Christina Leah B., et al.
Publicado: (2013)

Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients
por: Leaf, Sofia, et al.
Publicado: (2021)

Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
por: Zhang, Shengliang, et al.
Publicado: (2022)

Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
por: Zhao, Shuai, et al.
Publicado: (2021)

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection
por: Zhou, Lanlan, et al.
Publicado: (2020)

Case report of prostate ductal adenocarcinoma presenting with hematuria
por: Pawlowski, Jamie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_39eqbeskelqvlbqp3qehdso0r7